Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966;45:139–160.
Tsai HM, Lian EC. Antibodies to von Willebrand factor–cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585–1594.
Sarode R, Bandarenko N, Brecher ME et al.. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014;29:148–167.
Reese JA, Bougie DW, Curtis BR et al.. Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the Blood Center of Wisconsin. Am J Hematol 2015;90:406–410.
Tefferi A, Thiele J, Orazi A et al.. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097.
- Search Google Scholar
- Export Citation
. Tefferi A Thiele J Orazi A Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092– 1097.
Swierczek SI, Piterkova L, Jelinek J et al.. Methylation of AR locus does not always reflect X chromosome inactivation state. Blood 2012;119:e100–109.
Kiladjian JJ, Cassinat B, Chevret S et al.. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065–3072.
Zuber J, Martinez F, Droz D et al.. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 2002;81:321–331.
Deutsch M, Manesis EK, Hadziyannis E et al.. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. Scand J Gastroenterol 2007;42:408–409.
Yagita M, Uemura M, Nakamura T et al.. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005;42:420–421.
Sacchi S, Kantarjian H, O'Brien S et al.. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401–2407.
Ramos-Casals M, Garcia-Carrasco M, Lopez-Medrano F et al.. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003;82:87–96.
Shammas F, Meyer P, Heikkila R et al.. Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea. Acta Haematol 1997;97:184–186.
Kitano K, Gibo Y, Kamijo A et al.. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Haematologica 2006;91(8 Suppl):ECR34.
Ravandi-Kashani F, Cortes J, Talpaz M et al.. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer 1999;85:2583–2588.
Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. Am J Med 1989;87:9N–15N.
Rialon KL, Speicher PJ, Ceppa EP et al.. Outcomes following splenectomy in patients with myeloid neoplasms. J Surg Oncol 2015;111:389–395.
Dubois L, Gray DK. Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg 2010;53:349–355.